TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Glo-BNHL Central Review of Imaging and Clinical Data

Medical imaging services
West Midlands (UKG)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: THE UNIVERSITY OF BIRMINGHAM: "Glo-BNHL Central Review of Imaging and Clinical Data". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityTHE UNIVERSITY OF BIRMINGHAMScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: THE UNIVERSITY OF BIRMINGHAM
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for THE UNIVERSITY OF BIRMINGHAM. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
Not availableNo published reports
Bid counts are not published for this buyer
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 6 active published awards; 0 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityTHE UNIVERSITY OF BIRMINGHAM
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published21 Jan 2025, 09:30 GMT
Last source update21 Jan 2025, 09:30 GMT
Recurring procurementNot published
ClassificationMedical imaging services
Delivery area
West Midlands (UKG)
OCIDocds-h6vhtk-04d4e5
What is being bought
Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform central review of imaging and clinical data, therefore a suitable third-party vendor must be engaged for this critical work.
What changed
From the official release history
  1. Status changed to complete
    21 Jan 2025, 09:30 GMT
  2. Official notice release published
    21 Jan 2025, 09:30 GMT
  3. Buyer information updated
    21 Jan 2025, 09:30 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform central review of imaging and clinical data, therefore a suitable third-party vendor must be engaged for this critical work.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    21 Jan 2025, 09:30 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 13 Dec 2024, 00:00 GMT · £685,056
Commercial outcome and competition
Awards
Medidata Solutions International Ltd
Not published · Not published · active
Contracts
Contract
£685,056 · signed 13 Dec 2024, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

THE UNIVERSITY OF BIRMINGHAM

Contracting authority GB-UKPRN-10006840
View buyer profile

  • THE UNIVERSITY OF BIRMINGHAM
    buyer

    GB-UKPRN: 10006840
    Edgbaston, BIRMINGHAM, UKG31, B152TT
    K.Samsonik@bham.ac.uk

  • Medidata Solutions International Ltd
    supplier

    GB-COH: 09639306
    London, UKI3

  • University of Birmingham
    reviewBody

    Edgbaston
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleGlo-BNHL A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Glo-BNHL is an international multi-arm clinical trial developed in collaboration with a number of key childhood cancer research organisations, including Innovative Therapies for Children with Cancer (ITCC) and the European Intergroup for Childhood NHL (EICNHL) in Europe, and the Children's Oncology Group (COG) in North America. The trial will be delivered globally with support from these organisations and in partnership with the C17 Council in Canada and the Australia and New Zealand Children's Haematology and Oncology Group (ANZCHOG). The trial is jointly funded by Cancer Research UK, Fight Kids Cancer and industry collaborators (currently ADC Therapeutics and Regeneron Pharmaceuticals). The funding provided is contingent upon the use of vendors with a track record of delivering clinical trials of this kind. The Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham is not able to perform central review of imaging and clinical data, therefore a suitable third-party vendor must be engaged for this critical work. The preferred vendor for central review of imaging and clinical data is Medidata. Medidata have been selected because:  None of the vendors who applied through the open tender process were successful (Medidata did not apply)  Medidata already operate the Glo-BNHL Electronic Data Capture (EDC) system which will allow for seamless integration of the central review with the rest of the trial data  They have experience in the relevant disease group, B-cell Non-Hodgkin's Lymphoma (B-NHL)  They have access to a CRF library for B-NHL and to industry partner CRF libraries  They are able to deliver a live global central review system within 6-8 weeks  They are able to demonstrate compliance with regulations across all global regions  They are able to implement major trial protocol amendments (e.g. new treatment arms) without requiring temporary closures of existing live aspects of the database  They can provide visibility on all imaging activity, including access to DICOM files/images, videos, imaging data and metadata  They are able to review and mask Patient Health Information (PHI)  They offer single sign-on and EDC unification  They can provide regulatory compliant digital storage and archival  They provide upload check to sites and raise data queries  They can allow real-time, read-only access to UoB and can work with any third party imaging specialist to carry out the review  They perform data reconciliation between imaging and the EDC When deciding upon a partner to work with us on Glo-BNHL, we felt the expertise detailed above, as well as the following other considerations, made Medidata the right choice for this trial: 1. Experience working with CRCTU o Medidata are familiar with our way of working and the Glo-BNHL study; existing Glo-BNHL EDC protocols and documentation can be quickly adapted, thereby saving time and providing greater value for money o There is no lag time associated with familiarising the Medidata team with the study o Sites will not be required to work with multiple providers and will instead use the Medidata system they are familiar with o We have an established relationship with Medidata and they have already demonstrated their ability to deliver, therefore risk is mitigated by working with them again 2. There is an existing MSA between Medidata and UoB o Having an MSA in place significantly speeds up the process of contracting with Medidata and means we will not delay the progress of the trial, benefiting the patients waiting for novel treatments o We can begin working with Medidata upon execution of a Work Order, significantly reducing the timelines for opening the study as well as reducing the burden on the University support services